<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37240332</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>19</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Limited Association between Antibodies to Oxidized Low-Density Lipoprotein and Vascular Affection in Patients with Established Systemic Lupus Erythematosus.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">8987</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms24108987</ELocationID><Abstract><AbstractText>Patients with systemic lupus erythematosus (SLE) are at an increased risk of cardiovascular disease. We aimed to evaluate whether antibodies to oxidized low-density lipoprotein (anti-oxLDL) were associated with subclinical atherosclerosis in patients with different SLE phenotypes (lupus nephritis, antiphospholipid syndrome, and skin and joint involvement). Anti-oxLDL was measured by enzyme-linked immunosorbent assay in 60 patients with SLE, 60 healthy controls (HCs) and 30 subjects with anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). Intima-media thickness (IMT) assessment of vessel walls and plaque occurrence were recorded using high-frequency ultrasound. In the SLE cohort, anti-oxLDL was again assessed in 57 of the 60 individuals approximately 3 years later. The levels of anti-oxLDL in the SLE group (median 5829 U/mL) were not significantly different from those in the HCs group (median 4568 U/mL), while patients with AAV showed significantly higher levels (median 7817 U/mL). The levels did not differ between the SLE subgroups. A significant correlation was found with IMT in the common femoral artery in the SLE cohort, but no association with plaque occurrence was observed. The levels of anti-oxLDL antibodies in the SLE group were significantly higher at inclusion compared to 3 years later (median 5707 versus 1503 U/mL, <i>p</i> &lt; 0.0001). Overall, we found no convincing support for strong associations between vascular affection and anti-oxLDL antibodies in SLE.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wirestam</LastName><ForeName>Lina</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection, Linkoping University, SE-581 85 Linkoping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>J&#xf6;nsson</LastName><ForeName>Frida</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-9032-6033</Identifier><AffiliationInfo><Affiliation>Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection, Linkoping University, SE-581 85 Linkoping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Enocsson</LastName><ForeName>Helena</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-2125-2931</Identifier><AffiliationInfo><Affiliation>Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection, Linkoping University, SE-581 85 Linkoping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Svensson</LastName><ForeName>Christina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-2615-2240</Identifier><AffiliationInfo><Affiliation>Department of Clinical Physiology, University Hospital and Department of Health, Medicine and Caring Sciences, Linkoping University, SE-581 85 Linkoping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nephrology in Linkoping, Department of Health, Medicine and Caring Sciences, Link&#xf6;ping University, SE-581 85 Linkoping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wetter&#xf6;</LastName><ForeName>Jonas</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6916-5490</Identifier><AffiliationInfo><Affiliation>Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection, Linkoping University, SE-581 85 Linkoping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zachrisson</LastName><ForeName>Helene</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Clinical Physiology, University Hospital and Department of Health, Medicine and Caring Sciences, Linkoping University, SE-581 85 Linkoping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eriksson</LastName><ForeName>Per</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection, Linkoping University, SE-581 85 Linkoping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sj&#xf6;wall</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-0900-2048</Identifier><AffiliationInfo><Affiliation>Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection, Linkoping University, SE-581 85 Linkoping, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R-939149</GrantID><Agency>the Swedish Rheumatism Association</Agency><Country/></Grant><Grant><GrantID>ALF Grants</GrantID><Agency>the Region &#xd6;sterg&#xf6;tland</Agency><Country/></Grant><Grant><GrantID>2022</GrantID><Agency>the Gustafsson Foundation</Agency><Country/></Grant><Grant><GrantID>FAI-2020-0663</GrantID><Agency>the King Gustaf V's 80-year Anniversary foundation</Agency><Country/></Grant><Grant><GrantID>2021</GrantID><Agency>the King Gustaf V and Queen Victoria's Freemasons foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008077">Lipoproteins, LDL</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059168" MajorTopicYN="N">Carotid Intima-Media Thickness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050197" MajorTopicYN="Y">Atherosclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058226" MajorTopicYN="Y">Plaque, Atherosclerotic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008077" MajorTopicYN="N">Lipoproteins, LDL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SLE</Keyword><Keyword MajorTopicYN="N">anti-oxidized low-density lipoprotein</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">cardiovascular disease</Keyword><Keyword MajorTopicYN="N">intima-media thickness</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>27</Day><Hour>9</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>27</Day><Hour>1</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37240332</ArticleId><ArticleId IdType="pmc">PMC10219253</ArticleId><ArticleId IdType="doi">10.3390/ijms24108987</ArticleId><ArticleId IdType="pii">ijms24108987</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hartley A., Haskard D., Khamis R. Oxidized LDL and anti-oxidized LDL antibodies in atherosclerosis-Novel insights and future directions in diagnosis and therapy. Trends Cardiovasc. Med. 2019;29:22&#x2013;26. doi: 10.1016/j.tcm.2018.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcm.2018.05.010</ArticleId><ArticleId IdType="pubmed">29934015</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowak B., Madej M., Luczak A., Malecki R., Wiland P. Disease Activity, Oxidized-LDL Fraction and Anti-Oxidized LDL Antibodies Influence Cardiovascular Risk in Rheumatoid Arthritis. Adv. Clin. Exp. Med. 2016;25:43&#x2013;50. doi: 10.17219/acem/29847.</Citation><ArticleIdList><ArticleId IdType="doi">10.17219/acem/29847</ArticleId><ArticleId IdType="pubmed">26935497</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Berg V.J., Vroegindewey M.M., Kardys I., Boersma E., Haskard D., Hartley A., Khamis R. Anti-Oxidized LDL Antibodies and Coronary Artery Disease: A Systematic Review. Antioxidants. 2019;8:484. doi: 10.3390/antiox8100484.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox8100484</ArticleId><ArticleId IdType="pmc">PMC6826549</ArticleId><ArticleId IdType="pubmed">31618991</ArticleId></ArticleIdList></Reference><Reference><Citation>Svensson C., Eriksson P., Zachrisson H., Sjowall C. High-Frequency Ultrasound of Multiple Arterial Areas Reveals Increased Intima Media Thickness, Vessel Wall Appearance, and Atherosclerotic Plaques in Systemic Lupus Erythematosus. Front. Med. 2020;7:581336. doi: 10.3389/fmed.2020.581336.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.581336</ArticleId><ArticleId IdType="pmc">PMC7581856</ArticleId><ArticleId IdType="pubmed">33163501</ArticleId></ArticleIdList></Reference><Reference><Citation>Zachrisson H., Svensson C., Dremetsika A., Eriksson P. An extended high-frequency ultrasound protocol for detection of vessel wall inflammation. Clin. Physiol. Funct. Imaging. 2018;38:586&#x2013;594. doi: 10.1111/cpf.12450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cpf.12450</ArticleId><ArticleId IdType="pubmed">28795494</ArticleId></ArticleIdList></Reference><Reference><Citation>Alhusain A., Bruce I.N. Cardiovascular risk and inflammatory rheumatic diseases. Clin. Med. 2013;13:395&#x2013;397. doi: 10.7861/clinmedicine.13-4-395.</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmedicine.13-4-395</ArticleId><ArticleId IdType="pmc">PMC4954310</ArticleId><ArticleId IdType="pubmed">23908513</ArticleId></ArticleIdList></Reference><Reference><Citation>Yazdany J., Pooley N., Langham J., Nicholson L., Langham S., Embleton N., Wang X., Desta B., Barut V., Hammond E. Systemic lupus erythematosus; stroke and myocardial infarction risk: A systematic review and meta-analysis. RMD Open. 2020;6:e001247. doi: 10.1136/rmdopen-2020-001247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2020-001247</ArticleId><ArticleId IdType="pmc">PMC7722272</ArticleId><ArticleId IdType="pubmed">32900883</ArticleId></ArticleIdList></Reference><Reference><Citation>Enocsson H., Karlsson J., Li H.Y., Wu Y., Kushner I., Wettero J., Sjowall C. The Complex Role of C-Reactive Protein in Systemic Lupus Erythematosus. J. Clin. Med. 2021;10:5837. doi: 10.3390/jcm10245837.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10245837</ArticleId><ArticleId IdType="pmc">PMC8708507</ArticleId><ArticleId IdType="pubmed">34945133</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou M.G. Cardiovascular disease risk in antiphospholipid syndrome: Thrombo-inflammation and atherothrombosis. J. Autoimmun. 2022;128:102813. doi: 10.1016/j.jaut.2022.102813.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2022.102813</ArticleId><ArticleId IdType="pubmed">35247655</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Mattisson I., Rattik S., Bjorkbacka H., Ljungcrantz I., Terrinoni M., Lebens M., Holmgren J., Fredrikson G.N., Gullstrand B., Bengtsson A.A., et al. Immune responses against oxidized LDL as possible targets for prevention of atherosclerosis in systemic lupus erythematosus. Vasc. Pharmacol. 2021;140:106863. doi: 10.1016/j.vph.2021.106863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vph.2021.106863</ArticleId><ArticleId IdType="pubmed">33857652</ArticleId></ArticleIdList></Reference><Reference><Citation>Iseme R.A., McEvoy M., Kelly B., Agnew L., Walker F.R., Handley T., Oldmeadow C., Attia J., Boyle M. A role for autoantibodies in atherogenesis. Cardiovasc. Res. 2017;113:1102&#x2013;1112. doi: 10.1093/cvr/cvx112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvx112</ArticleId><ArticleId IdType="pubmed">28899001</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowak B., Szmyrka-Kaczmarek M., Durazinska A., Plaksej R., Borysewicz K., Korman L., Wiland P. Anti-ox-LDL antibodies and anti-ox-LDL-B2GPI antibodies in patients with systemic lupus erythematosus. Adv. Clin. Exp. Med. 2012;21:331&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">23214196</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Y., Wu T., Zhang T., Han J., Habazi D., Saxena R., Mohan C. Elevated oxidized lipids, anti-lipid autoantibodies and oxidized lipid immune complexes in active SLE. Clin. Immunol. 2019;205:43&#x2013;48. doi: 10.1016/j.clim.2019.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2019.05.004</ArticleId><ArticleId IdType="pubmed">31075396</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Zumaquero J.M., Tinahones F.J., De Ramon E., Camps M., Garrido L., Soriguer F.J. Association of biological markers of activity of systemic lupus erythematosus with levels of anti-oxidized low-density lipoprotein antibodies. Rheumatology. 2004;43:510&#x2013;513. doi: 10.1093/rheumatology/keh109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keh109</ArticleId><ArticleId IdType="pubmed">14872100</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaarala O., Alfthan G., Jauhiainen M., Leirisalo-Repo M., Aho K., Palosuo T. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet. 1993;341:923&#x2013;925. doi: 10.1016/0140-6736(93)91213-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0140-6736(93)91213-6</ArticleId><ArticleId IdType="pubmed">8096266</ArticleId></ArticleIdList></Reference><Reference><Citation>Parodis I., Stockfelt M., Sjowall C. B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice. Front. Med. 2020;7:316. doi: 10.3389/fmed.2020.00316.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.00316</ArticleId><ArticleId IdType="pmc">PMC7381321</ArticleId><ArticleId IdType="pubmed">32754605</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamialahmadi T., Baratzadeh F., Reiner Z., Mannarino M.R., Cardenia V., Simental-Mendia L.E., Pirro M., Watts G.F., Sahebkar A. The Effects of Statin Therapy on Oxidized LDL and Its Antibodies: A Systematic Review and Meta-Analysis. Oxid. Med. Cell Longev. 2022;2022:7850659. doi: 10.1155/2022/7850659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/7850659</ArticleId><ArticleId IdType="pmc">PMC9359854</ArticleId><ArticleId IdType="pubmed">35958018</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu R., Svenungsson E., Gunnarsson I., Haegerstrand-Gillis C., Andersson B., Lundberg I., Elinder L.S., Frostegard J. Antibodies to adult human endothelial cells cross-react with oxidized low-density lipoprotein and beta 2-glycoprotein I (beta 2-GPI) in systemic lupus erythematosus. Clin. Exp. Immunol. 1999;115:561&#x2013;566. doi: 10.1046/j.1365-2249.1999.00830.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2249.1999.00830.x</ArticleId><ArticleId IdType="pmc">PMC1905246</ArticleId><ArticleId IdType="pubmed">10193434</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoenfeld Y., Wu R., Dearing L.D., Matsuura E. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective? Circulation. 2004;110:2552&#x2013;2558. doi: 10.1161/01.CIR.0000143225.07377.EA.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000143225.07377.EA</ArticleId><ArticleId IdType="pubmed">15505108</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao D., Ogawa H., Wang X., Cameron G.S., Baty D.E., Dlott J.S., Triplett D.A. Oxidized low-density lipoprotein and autoimmune antibodies in patients with antiphospholipid syndrome with a history of thrombosis. Am. J. Clin. Pathol. 2001;116:760&#x2013;767. doi: 10.1309/1RYQ-Q2AJ-CKF7-YCDE.</Citation><ArticleIdList><ArticleId IdType="doi">10.1309/1RYQ-Q2AJ-CKF7-YCDE</ArticleId><ArticleId IdType="pubmed">11710695</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayem G., Nicaise-Roland P., Palazzo E., de Bandt M., Tubach F., Weber M., Meyer O. Anti-oxidized low-density-lipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome. Lupus. 2001;10:346&#x2013;351. doi: 10.1191/096120301667475689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096120301667475689</ArticleId><ArticleId IdType="pubmed">11403265</ArticleId></ArticleIdList></Reference><Reference><Citation>Salonen J.T., Yla-Herttuala S., Yamamoto R., Butler S., Korpela H., Salonen R., Nyyssonen K., Palinski W., Witztum J.L. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 1992;339:883&#x2013;887. doi: 10.1016/0140-6736(92)90926-T.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0140-6736(92)90926-T</ArticleId><ArticleId IdType="pubmed">1348295</ArticleId></ArticleIdList></Reference><Reference><Citation>Svenungsson E., Engelbertsen D., Wigren M., Gustafsson J.T., Gunnarsson I., Elvin K., Jensen-Urstad K., Fredrikson G.N., Nilsson J. Decreased levels of autoantibodies against apolipoprotein B-100 antigens are associated with cardiovascular disease in systemic lupus erythematosus. Clin. Exp. Immunol. 2015;181:417&#x2013;426. doi: 10.1111/cei.12651.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.12651</ArticleId><ArticleId IdType="pmc">PMC4557377</ArticleId><ArticleId IdType="pubmed">25959453</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurien B.T., Fesmire J., Anderson C.J., Scofield R.H. Anti-Ro and Concomitant Anti-La Autoantibodies Strongly Associated With Anti-oxLDL or Anti-Phospholipid Antibody in Systemic Lupus Erythematosus. J. Clin. Rheumatol. 2016;22:418&#x2013;425. doi: 10.1097/RHU.0000000000000429.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RHU.0000000000000429</ArticleId><ArticleId IdType="pubmed">27870764</ArticleId></ArticleIdList></Reference><Reference><Citation>Bengtsson A., Nezlin R., Shoenfeld Y., Sturfelt G. DNA levels in circulating immune complexes decrease at severe SLE flares-correlation with complement component C1q. J. Autoimmun. 1999;13:111&#x2013;119. doi: 10.1006/jaut.1999.0300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jaut.1999.0300</ArticleId><ArticleId IdType="pubmed">10441175</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohrabian A., Parodis I., Carlstromer-Berthen N., Frodlund M., J&#xf6;nsen A., Zickert A., Sj&#xf6;wall C., Bengtsson A.A., Gunnarsson I., Ronnelid J. Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus. Arthritis Res. Ther. 2019;21:259. doi: 10.1186/s13075-019-2056-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-019-2056-y</ArticleId><ArticleId IdType="pmc">PMC6884768</ArticleId><ArticleId IdType="pubmed">31783909</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturfelt G., Bengtsson A., Klint C., Nived O., Sj&#xf6;holm A., Truedsson L. Novel roles of complement in systemic lupus erythematosus--hypothesis for a pathogenetic vicious circle. J. Rheumatol. 2000;27:661&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">10743804</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiopu A., Bengtsson J., Soderberg I., Janciauskiene S., Lindgren S., Ares M.P., Shah P.K., Carlsson R., Nilsson J., Fredrikson G.N. Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation. 2004;110:2047&#x2013;2052. doi: 10.1161/01.CIR.0000143162.56057.B5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000143162.56057.B5</ArticleId><ArticleId IdType="pubmed">15451805</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirestam L., Saleh M., Svensson C., Compagno M., Zachrisson H., Wettero J., Sjowall C. Plasma osteopontin versus intima media thickness of the common carotid arteries in well-characterised patients with systemic lupus erythematosus. Lupus. 2021;30:1244&#x2013;1253. doi: 10.1177/09612033211013898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033211013898</ArticleId><ArticleId IdType="pmc">PMC8209759</ArticleId><ArticleId IdType="pubmed">33957796</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., Schaller J.G., Talal N., Winchester R.J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271&#x2013;1277. doi: 10.1002/art.1780251101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780251101</ArticleId><ArticleId IdType="pubmed">7138600</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson P., Jacobsson L., Lindell A., Nilsson J.A., Skogh T. Improved outcome in Wegener&#x2019;s granulomatosis and microscopic polyangiitis? A retrospective analysis of 95 cases in two cohorts. J. Intern. Med. 2009;265:496&#x2013;506. doi: 10.1111/j.1365-2796.2008.02060.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2796.2008.02060.x</ArticleId><ArticleId IdType="pubmed">19141094</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts R., Lane S., Hanslik T., Hauser T., Hellmich B., Koldingsnes W., Mahr A., Segelmark M., Cohen-Tervaert J.W., Scott D. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann. Rheum. Dis. 2007;66:222&#x2013;227. doi: 10.1136/ard.2006.054593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2006.054593</ArticleId><ArticleId IdType="pmc">PMC1798520</ArticleId><ArticleId IdType="pubmed">16901958</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukhtyar C., Lee R., Brown D., Carruthers D., Dasgupta B., Dubey S., Flossmann O., Hall C., Hollywood J., Jayne D., et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3) Ann. Rheum. Dis. 2009;68:1827&#x2013;1832. doi: 10.1136/ard.2008.101279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2008.101279</ArticleId><ArticleId IdType="pubmed">19054820</ArticleId></ArticleIdList></Reference><Reference><Citation>Enocsson H., Wirestam L., Dahle C., Padyukov L., J&#xf6;nsen A., Urowitz M.B., Gladman D.D., Romero-Diaz J., Bae S.C., Fortin P.R., et al. Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. J. Autoimmun. 2020;106:102340. doi: 10.1016/j.jaut.2019.102340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2019.102340</ArticleId><ArticleId IdType="pubmed">31629628</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlsson J., Wettero J., Weiner M., Ronnelid J., Fernandez-Botran R., Sjowall C. Associations of C-reactive protein isoforms with systemic lupus erythematosus phenotypes and disease activity. Arthritis Res. Ther. 2022;24:139. doi: 10.1186/s13075-022-02831-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-022-02831-9</ArticleId><ArticleId IdType="pmc">PMC9188243</ArticleId><ArticleId IdType="pubmed">35690780</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopprasch S., Bornstein S.R., Bergmann S., Graessler J., Hohenstein B., Julius U. Long-term follow-up of circulating oxidative stress markers in patients undergoing lipoprotein apheresis by Direct Adsorption of Lipids (DALI) Atheroscler. Suppl. 2017;30:115&#x2013;121. doi: 10.1016/j.atherosclerosissup.2017.05.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosissup.2017.05.029</ArticleId><ArticleId IdType="pubmed">29096826</ArticleId></ArticleIdList></Reference><Reference><Citation>Zdanowska N., Owczarczyk-Saczonek A., Czerwi&#x144;&#x15b;ka J., Nowakowski J., Kozera-&#x17b;ywczyk A., Owczarek W., Zdanowski W., Swacha Z., Placek W. Methotrexate decreases oxidized low-density lipoprotein serum levels in patients with plaque psoriasis&#x2014;Results of a preliminary study. Acta Pol. Pharm.-Drug Res. 2021;78:121&#x2013;127. doi: 10.32383/appdr/133654.</Citation><ArticleIdList><ArticleId IdType="doi">10.32383/appdr/133654</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>